{"id": "RL33605", "inputs": [{"text": "rising health care costs have for many years focused congressional attention upon the development and availability of prescription drugs .", "tokens": ["rising", "health", "care", "costs", "have", "for", "many", "years", "focused", "congressional", "attention", "upon", "the", "development", "and", "availability", "of", "prescription", "drugs", "."], "sentence_id": 1, "word_count": 20}, {"text": "recently , the presence of \"authorized generic\" pharmaceuticals in the drug marketplace has been the subject of congressional concern .", "tokens": ["recently", ",", "the", "presence", "of", "``", "authorized", "generic", "''", "pharmaceuticals", "in", "the", "drug", "marketplace", "has", "been", "the", "subject", "of", "congressional", "concern", "."], "sentence_id": 2, "word_count": 22}, {"text": "an \"authorized generic\" is a pharmaceutical that is marketed by or on behalf of a brand - named drug company , but is sold under a generic name .", "tokens": ["an", "``", "authorized", "generic", "''", "is", "a", "pharmaceutical", "that", "is", "marketed", "by", "or", "on", "behalf", "of", "a", "brand", "-", "named", "drug", "company", ",", "but", "is", "sold", "under", "a", "generic", "name", "."], "sentence_id": 3, "word_count": 31}, {"text": "the brand - name firm may distribute the drug under its own auspices or via a license to a generic drug company .", "tokens": ["the", "brand", "-", "name", "firm", "may", "distribute", "the", "drug", "under", "its", "own", "auspices", "or", "via", "a", "license", "to", "a", "generic", "drug", "company", "."], "sentence_id": 4, "word_count": 23}, {"text": "the price of this \"authorized copy\" is ordinarily lower than that of the brand - name drug .", "tokens": ["the", "price", "of", "this", "``", "authorized", "copy", "''", "is", "ordinarily", "lower", "than", "that", "of", "the", "brand", "-", "name", "drug", "."], "sentence_id": 5, "word_count": 20}, {"text": "some sources refer to authorized generics as \"branded,\" \"flanking,\" or \"pseudo\" generics. .", "tokens": ["some", "sources", "refer", "to", "authorized", "generics", "as", "``", "branded", ",", "''", "``", "flanking", ",", "''", "or", "``", "pseudo", "''", "generics", ".", "."], "sentence_id": 6, "word_count": 22}, {"text": "authorized generics may be pro - consumer in that they potentially increase competition and lower prices , particularly in the short - term .", "tokens": ["authorized", "generics", "may", "be", "pro", "-", "consumer", "in", "that", "they", "potentially", "increase", "competition", "and", "lower", "prices", ",", "particularly", "in", "the", "short", "-", "term", "."], "sentence_id": 7, "word_count": 24}, {"text": "they have nonetheless proven controversial .", "tokens": ["they", "have", "nonetheless", "proven", "controversial", "."], "sentence_id": 8, "word_count": 6}, {"text": "authorized generics ordinarily enter the market at about the time the brand - name drug company's patents are set to expire .", "tokens": ["authorized", "generics", "ordinarily", "enter", "the", "market", "at", "about", "the", "time", "the", "brand", "-", "name", "drug", "company", "'s", "patents", "are", "set", "to", "expire", "."], "sentence_id": 9, "word_count": 23}, {"text": "some observers argue that such products may possibly discourage independent generic firms both from challenging drug patents and from selling their own generic products .", "tokens": ["some", "observers", "argue", "that", "such", "products", "may", "possibly", "discourage", "independent", "generic", "firms", "both", "from", "challenging", "drug", "patents", "and", "from", "selling", "their", "own", "generic", "products", "."], "sentence_id": 10, "word_count": 25}, {"text": "the potential diminution in independent generic incentives may in turn lead to less desire on the part of brand - name firms to market authorized generics themselves .", "tokens": ["the", "potential", "diminution", "in", "independent", "generic", "incentives", "may", "in", "turn", "lead", "to", "less", "desire", "on", "the", "part", "of", "brand", "-", "name", "firms", "to", "market", "authorized", "generics", "themselves", "."], "sentence_id": 11, "word_count": 28}, {"text": "legal challenges to authorized generics practice have thus far been unsuccessful in the courts .", "tokens": ["legal", "challenges", "to", "authorized", "generics", "practice", "have", "thus", "far", "been", "unsuccessful", "in", "the", "courts", "."], "sentence_id": 12, "word_count": 15}, {"text": "legislation has been introduced regarding authorized generic practice , however .", "tokens": ["legislation", "has", "been", "introduced", "regarding", "authorized", "generic", "practice", ",", "however", "."], "sentence_id": 13, "word_count": 11}, {"text": "legislation introduced but not yet enacted in the 112 th congress , h.r .", "tokens": ["legislation", "introduced", "but", "not", "yet", "enacted", "in", "the", "112", "th", "congress", ",", "h.r", "."], "sentence_id": 14, "word_count": 14}, {"text": "741 and s. 373 , proposed to prevent pharmaceutical firms from selling authorized generics .", "tokens": ["741", "and", "s.", "373", ",", "proposed", "to", "prevent", "pharmaceutical", "firms", "from", "selling", "authorized", "generics", "."], "sentence_id": 15, "word_count": 15}, {"text": "this report presents an analysis of the innovation and public health issues relating to authorized generic drugs .", "tokens": ["this", "report", "presents", "an", "analysis", "of", "the", "innovation", "and", "public", "health", "issues", "relating", "to", "authorized", "generic", "drugs", "."], "sentence_id": 16, "word_count": 18}, {"text": "the report begins with a review of the procedures through which independent generic drug companies receive government permission to market their products and resolve patent disputes with brand - name firms .", "tokens": ["the", "report", "begins", "with", "a", "review", "of", "the", "procedures", "through", "which", "independent", "generic", "drug", "companies", "receive", "government", "permission", "to", "market", "their", "products", "and", "resolve", "patent", "disputes", "with", "brand", "-", "name", "firms", "."], "sentence_id": 17, "word_count": 32}, {"text": "it then provides detailed background information pertaining to the concept of authorized generics and assesses their potential impact upon patent challenges and consumer welfare .", "tokens": ["it", "then", "provides", "detailed", "background", "information", "pertaining", "to", "the", "concept", "of", "authorized", "generics", "and", "assesses", "their", "potential", "impact", "upon", "patent", "challenges", "and", "consumer", "welfare", "."], "sentence_id": 18, "word_count": 25}, {"text": "the report closes with a summary of congressional issues and possible alternatives .", "tokens": ["the", "report", "closes", "with", "a", "summary", "of", "congressional", "issues", "and", "possible", "alternatives", "."], "sentence_id": 19, "word_count": 13}, {"text": "the practice of authorized generics has arisen within a complex statutory framework established by the drug price competition and patent term restoration act of 1984 , legislation more commonly known as the hatch - waxman act .", "tokens": ["the", "practice", "of", "authorized", "generics", "has", "arisen", "within", "a", "complex", "statutory", "framework", "established", "by", "the", "drug", "price", "competition", "and", "patent", "term", "restoration", "act", "of", "1984", ",", "legislation", "more", "commonly", "known", "as", "the", "hatch", "-", "waxman", "act", "."], "sentence_id": 20, "word_count": 37}, {"text": "under parameters established by that statute , a manufacturer that wishes to sell a generic drug must both obtain marketing approval from the food and drug administration ( fda ) and account for any patent rights that pertain to that product .", "tokens": ["under", "parameters", "established", "by", "that", "statute", ",", "a", "manufacturer", "that", "wishes", "to", "sell", "a", "generic", "drug", "must", "both", "obtain", "marketing", "approval", "from", "the", "food", "and", "drug", "administration", "(", "fda", ")", "and", "account", "for", "any", "patent", "rights", "that", "pertain", "to", "that", "product", "."], "sentence_id": 21, "word_count": 42}, {"text": "this report first addresses fda marketing approval procedures for generic drugs , and then turns to possible patent implications .", "tokens": ["this", "report", "first", "addresses", "fda", "marketing", "approval", "procedures", "for", "generic", "drugs", ",", "and", "then", "turns", "to", "possible", "patent", "implications", "."], "sentence_id": 22, "word_count": 20}, {"text": "although congress made significant amendments to the hatch - waxman act as recently as 2003 , authorized generics were not subject to discussion at that time .", "tokens": ["although", "congress", "made", "significant", "amendments", "to", "the", "hatch", "-", "waxman", "act", "as", "recently", "as", "2003", ",", "authorized", "generics", "were", "not", "subject", "to", "discussion", "at", "that", "time", "."], "sentence_id": 23, "word_count": 27}, {"text": "the rise of this practice , as well as the vigor of the debate surrounding it , suggests both the pace of change within the industry and the prominence of the pharmaceutical industry within the national public health system .", "tokens": ["the", "rise", "of", "this", "practice", ",", "as", "well", "as", "the", "vigor", "of", "the", "debate", "surrounding", "it", ",", "suggests", "both", "the", "pace", "of", "change", "within", "the", "industry", "and", "the", "prominence", "of", "the", "pharmaceutical", "industry", "within", "the", "national", "public", "health", "system", "."], "sentence_id": 24, "word_count": 40}, {"text": "as discussion of authorized generics continues , congress may wish to have a sense of its legislative options .", "tokens": ["as", "discussion", "of", "authorized", "generics", "continues", ",", "congress", "may", "wish", "to", "have", "a", "sense", "of", "its", "legislative", "options", "."], "sentence_id": 25, "word_count": 19}, {"text": "should congress conclude that authorized generics are appropriate , then it may simply take no action .", "tokens": ["should", "congress", "conclude", "that", "authorized", "generics", "are", "appropriate", ",", "then", "it", "may", "simply", "take", "no", "action", "."], "sentence_id": 26, "word_count": 17}, {"text": "the opinions of the d.c. and fourth circuits suggest that , as currently drafted , the hatch - waxman act does not allow the fda to restrict the ability of brand - name firms to sell or approve of authorized generics .", "tokens": ["the", "opinions", "of", "the", "d.c.", "and", "fourth", "circuits", "suggest", "that", ",", "as", "currently", "drafted", ",", "the", "hatch", "-", "waxman", "act", "does", "not", "allow", "the", "fda", "to", "restrict", "the", "ability", "of", "brand", "-", "name", "firms", "to", "sell", "or", "approve", "of", "authorized", "generics", "."], "sentence_id": 27, "word_count": 42}, {"text": "absent legislative input , the fda may be unlikely to alter its interpretation of the hatch - waxman act in this respect in the future .", "tokens": ["absent", "legislative", "input", ",", "the", "fda", "may", "be", "unlikely", "to", "alter", "its", "interpretation", "of", "the", "hatch", "-", "waxman", "act", "in", "this", "respect", "in", "the", "future", "."], "sentence_id": 28, "word_count": 26}, {"text": "alternatively , congress could simply disallow authorized generics practice .", "tokens": ["alternatively", ",", "congress", "could", "simply", "disallow", "authorized", "generics", "practice", "."], "sentence_id": 29, "word_count": 10}, {"text": "unenacted bills introduced in the 112 th congress , h.r .", "tokens": ["unenacted", "bills", "introduced", "in", "the", "112", "th", "congress", ",", "h.r", "."], "sentence_id": 30, "word_count": 11}, {"text": "741 and s. 373 , would have prohibited nda holders from manufacturing , marketing , selling , or distributing an authorized generic drug .", "tokens": ["741", "and", "s.", "373", ",", "would", "have", "prohibited", "nda", "holders", "from", "manufacturing", ",", "marketing", ",", "selling", ",", "or", "distributing", "an", "authorized", "generic", "drug", "."], "sentence_id": 31, "word_count": 24}, {"text": "the term \"authorized generic drug\" was defined as \"any version of a listed drug ... that the holder of new drug application ... seeks to commence marketing , selling , or distributing , directly or indirectly , after receipt of a notice\" that an anda has been filed .", "tokens": ["the", "term", "``", "authorized", "generic", "drug", "''", "was", "defined", "as", "``", "any", "version", "of", "a", "listed", "drug", "...", "that", "the", "holder", "of", "new", "drug", "application", "...", "seeks", "to", "commence", "marketing", ",", "selling", ",", "or", "distributing", ",", "directly", "or", "indirectly", ",", "after", "receipt", "of", "a", "notice", "''", "that", "an", "anda", "has", "been", "filed", "."], "sentence_id": 32, "word_count": 53}, {"text": "drugs marketed by firms eligible for the 180-day generic exclusivity , or that were sold by anyone after that exclusivity has expired , were not considered to be authorized generic drugs .", "tokens": ["drugs", "marketed", "by", "firms", "eligible", "for", "the", "180-day", "generic", "exclusivity", ",", "or", "that", "were", "sold", "by", "anyone", "after", "that", "exclusivity", "has", "expired", ",", "were", "not", "considered", "to", "be", "authorized", "generic", "drugs", "."], "sentence_id": 33, "word_count": 32}, {"text": "another option is to require brand - name firms to file a supplemental nda , or a similar application , with the fda when they market authorized generics .", "tokens": ["another", "option", "is", "to", "require", "brand", "-", "name", "firms", "to", "file", "a", "supplemental", "nda", ",", "or", "a", "similar", "application", ",", "with", "the", "fda", "when", "they", "market", "authorized", "generics", "."], "sentence_id": 34, "word_count": 29}, {"text": "this filing would then place the brand - name firm in the same category as generic applicants who did not qualify as the first to file .", "tokens": ["this", "filing", "would", "then", "place", "the", "brand", "-", "name", "firm", "in", "the", "same", "category", "as", "generic", "applicants", "who", "did", "not", "qualify", "as", "the", "first", "to", "file", "."], "sentence_id": 35, "word_count": 27}, {"text": "in turn , the 180-day generic exclusivity period would then apply against the authorized generic .", "tokens": ["in", "turn", ",", "the", "180-day", "generic", "exclusivity", "period", "would", "then", "apply", "against", "the", "authorized", "generic", "."], "sentence_id": 36, "word_count": 16}, {"text": "notably , whether the 180-day generic exclusivity period strikes an appropriate balance between encouraging patent challenges and ensuring prompt access to generic medications is itself a contested proposition within the pharmaceutical industry .", "tokens": ["notably", ",", "whether", "the", "180-day", "generic", "exclusivity", "period", "strikes", "an", "appropriate", "balance", "between", "encouraging", "patent", "challenges", "and", "ensuring", "prompt", "access", "to", "generic", "medications", "is", "itself", "a", "contested", "proposition", "within", "the", "pharmaceutical", "industry", "."], "sentence_id": 37, "word_count": 33}, {"text": "discussion of the authorized generics issue may also prompt further reflection on the basic structure of incentives within the hatch - waxman act .", "tokens": ["discussion", "of", "the", "authorized", "generics", "issue", "may", "also", "prompt", "further", "reflection", "on", "the", "basic", "structure", "of", "incentives", "within", "the", "hatch", "-", "waxman", "act", "."], "sentence_id": 38, "word_count": 24}, {"text": "current interest in authorized generics reflects long - standing congressional concern for the appropriate balance between innovation and competition within the pharmaceutical industry .", "tokens": ["current", "interest", "in", "authorized", "generics", "reflects", "long", "-", "standing", "congressional", "concern", "for", "the", "appropriate", "balance", "between", "innovation", "and", "competition", "within", "the", "pharmaceutical", "industry", "."], "sentence_id": 39, "word_count": 24}, {"text": "although academic inquiry into authorized generics practice remains in its early phases , it is notable that knowledgeable commentators have reached disparate views of the benefits or detriments of this practice .", "tokens": ["although", "academic", "inquiry", "into", "authorized", "generics", "practice", "remains", "in", "its", "early", "phases", ",", "it", "is", "notable", "that", "knowledgeable", "commentators", "have", "reached", "disparate", "views", "of", "the", "benefits", "or", "detriments", "of", "this", "practice", "."], "sentence_id": 40, "word_count": 32}, {"text": "some observers stress that authorized generics benefit consumers by providing enhanced access to lower - cost alternatives to branded drugs , while others express concerns that authorized generics will defeat the incentives that independent generic firms possess to challenge pharmaceutical patents .", "tokens": ["some", "observers", "stress", "that", "authorized", "generics", "benefit", "consumers", "by", "providing", "enhanced", "access", "to", "lower", "-", "cost", "alternatives", "to", "branded", "drugs", ",", "while", "others", "express", "concerns", "that", "authorized", "generics", "will", "defeat", "the", "incentives", "that", "independent", "generic", "firms", "possess", "to", "challenge", "pharmaceutical", "patents", "."], "sentence_id": 41, "word_count": 42}, {"text": "future studies may shed additional light on the impact of authorized generics upon consumer welfare .", "tokens": ["future", "studies", "may", "shed", "additional", "light", "on", "the", "impact", "of", "authorized", "generics", "upon", "consumer", "welfare", "."], "sentence_id": 42, "word_count": 16}], "section_names": ["", "marketing approval and patent issues for generic drugs", "the concept of authorized generics", "concluding observations"], "section_lengths": [19, 3, 0, 20]}